Jiun‐I Lai

1.0k total citations
51 papers, 676 citations indexed

About

Jiun‐I Lai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jiun‐I Lai has authored 51 papers receiving a total of 676 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Jiun‐I Lai's work include Lung Cancer Treatments and Mutations (8 papers), Cancer Genomics and Diagnostics (7 papers) and Advanced Breast Cancer Therapies (6 papers). Jiun‐I Lai is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Cancer Genomics and Diagnostics (7 papers) and Advanced Breast Cancer Therapies (6 papers). Jiun‐I Lai collaborates with scholars based in Taiwan, United States and Poland. Jiun‐I Lai's co-authors include Peter Mu‐Hsin Chang, Ming‐Huang Chen, Chi‐Ying F. Huang, Wei-Shu Wang, Yi-Chun Lai, Shih-Chieh Chang, Gau‐Jun Tang, Wei‐Shu Wang, Chi‐Cheng Huang and Ling‐Ming Tseng and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Jiun‐I Lai

48 papers receiving 665 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jiun‐I Lai Taiwan	15	258	243	168	148	82	51	676
Manabu Shimomura Japan	14	245 0.9×	298 1.2×	307 1.8×	182 1.2×	123 1.5×	67	805
Mark Peter United Kingdom	10	159 0.6×	185 0.8×	150 0.9×	64 0.4×	68 0.8×	19	524
S. Post Germany	15	224 0.9×	127 0.5×	202 1.2×	144 1.0×	91 1.1×	45	648
Qingchen Wu China	16	182 0.7×	93 0.4×	211 1.3×	290 2.0×	123 1.5×	83	732
V. V. Moroz Russia	15	273 1.1×	122 0.5×	121 0.7×	253 1.7×	90 1.1×	91	746
Rebecca J. McClaine United States	13	159 0.6×	240 1.0×	135 0.8×	116 0.8×	62 0.8×	17	558
Urs von Holzen United States	15	180 0.7×	302 1.2×	200 1.2×	107 0.7×	56 0.7×	60	611
Cheng-Wen Hsiao Taiwan	15	255 1.0×	279 1.1×	419 2.5×	155 1.0×	188 2.3×	40	983
Seung‐Bum Ryoo South Korea	17	111 0.4×	221 0.9×	358 2.1×	73 0.5×	87 1.1×	76	753

Countries citing papers authored by Jiun‐I Lai

Since Specialization

Citations

This map shows the geographic impact of Jiun‐I Lai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiun‐I Lai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiun‐I Lai more than expected).

Fields of papers citing papers by Jiun‐I Lai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiun‐I Lai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiun‐I Lai. The network helps show where Jiun‐I Lai may publish in the future.

Co-authorship network of co-authors of Jiun‐I Lai

This figure shows the co-authorship network connecting the top 25 collaborators of Jiun‐I Lai. A scholar is included among the top collaborators of Jiun‐I Lai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiun‐I Lai. Jiun‐I Lai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dong, Mei, et al.. (2025). HDAC inhibitors modulate Hippo pathway signaling in hormone positive breast cancer. Clinical Epigenetics. 17(1). 37–37. 1 indexed citations

Tsai, Yi-Fang, et al.. (2024). Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population. Clinical and Experimental Medicine. 24(1). 185–185. 7 indexed citations

Hung, Yi‐Ping, et al.. (2024). Enhanced tumor control activities of anti-mPD-L1 antibody and antigen-presenting cell-like natural killer cell in an allograft model. BMC Cancer. 24(1). 136–136.

Lai, Jiun‐I, et al.. (2023). Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience. Thoracic Cancer. 15(4). 339–346. 1 indexed citations

Lai, Jiun‐I, Ting-Hao Kuo, Mei‐Hsuan Lee, et al.. (2023). Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients. The Oncologist. 29(4). e455–e466. 7 indexed citations

Kuo, Ting-Hao, Ta‐Chung Chao, Chun‐Yu Liu, et al.. (2023). Abstract P4-01-31: High Incidence of Palbociclib Related Neutropenia in Asian Patients Associated with Genetic Polymorphisms. Cancer Research. 83(5_Supplement). P4–1. 1 indexed citations

Tsai, Yi‐Fang, Pei‐Ju Lien, Chun‐Yu Liu, et al.. (2023). Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan. Breast Cancer. 31(2). 217–227.

Huang, Chi‐Cheng, Yi‐Fang Tsai, Chunyu Liu, et al.. (2023). Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast Cancer. Cancers. 15(18). 4475–4475. 3 indexed citations

Tsai, Yi‐Fang, Chun‐Yu Liu, Chih‐Yi Hsu, et al.. (2023). Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study. Breast Cancer Research. 25(1). 152–152. 2 indexed citations

10.

Liu, Chun‐Yu, et al.. (2022). IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target. Medical Oncology. 39(12). 242–242. 4 indexed citations

11.

Huang, Chi‐Cheng, Yi‐Fang Tsai, Chun‐Yu Liu, et al.. (2022). Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers. Annals of Surgical Oncology. 29(6). 3578–3590. 8 indexed citations

12.

Liu, Chun‐Yu, et al.. (2022). CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin–proteasome pathway in ER + breast cancer. Clinical & Translational Oncology. 24(11). 2120–2135. 5 indexed citations

13.

Lai, Jiun‐I, et al.. (2020). Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics. Frontiers in Oncology. 10. 561936–561936. 107 indexed citations

14.

Wang, W., C. Xu, Yingying Zhu, et al.. (2018). P2.03-09 The Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study. Journal of Thoracic Oncology. 13(10). S719–S719. 3 indexed citations

15.

Lai, Jiun‐I, Yin‐Quan Chen, Wei‐Fong Kao, et al.. (2017). The changes of red blood cell viscoelasticity and sports anemia in male 24-hr ultra-marathoners. Journal of the Chinese Medical Association. 81(5). 475–481. 12 indexed citations

16.

Lai, Jiun‐I, Chorng–Kuang How, Li-Hua Li, et al.. (2014). Early changes of the anemia phenomenon in male 100-km ultramarathoners. Journal of the Chinese Medical Association. 78(2). 108–113. 29 indexed citations

17.

Lai, Yi-Chun, et al.. (2012). Esophageal Squamous Cell Carcinoma with Solitary Renal Metastasis-A Case Report. Journal of Gastroenterology and Hepatology Research. 1(9). 230–232. 6 indexed citations

18.

Lai, Jiun‐I, et al.. (2012). Readmission to the intensive care unit: A population-based approach. Journal of the Formosan Medical Association. 111(9). 504–509. 20 indexed citations

19.

Lai, Jiun‐I, et al.. (2012). Tuberculous Pleural Effusion in the Elderly. SHILAP Revista de lepidopterología. 6(3). 224–228. 1 indexed citations

20.

Lai, Jiun‐I, et al.. (2011). Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. International Journal of Clinical Pharmacology and Therapeutics. 49(7). 461–466. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact